Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: A systematic review and meta-analysis

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 4, 2013, Pages 399-403

  Sun, Lei ^a   Yu, Shiying ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

bone metastases; denosumab; meta analysis; systematic review; zoledronic acid

Indexed keywords

DENOSUMAB; ZOLEDRONIC ACID;

ANEMIA; BACKACHE; BONE METASTASIS; CANCER SURVIVAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EMBASE; FATIGUE; HUMAN; INFECTION; JAW OSTEONECROSIS; MEDLINE; META ANALYSIS; MORBIDITY; NAUSEA; NEPHROTOXICITY; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; NEOPLASM STAGING; PATIENT SAFETY; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84881024325     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31824be20e     Document Type: Review

References (44)

1. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588-1594.
2. Costa L, Badia X, Chow E, et al. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer. 2008;16:879-889.
3. Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005-1007.
4. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334:488-493.
5. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377-387.
6. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996;14:2552-2559.
7. Kanis JA, Powles T, Paterson AH, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 1996;19:663-667.
8. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, doubleblind, multicenter, comparative trial. Cancer. 2003;98:1735-1744.
9. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314-3321.
10. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98:962-969.
11. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150-3157.
12. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94:1458-1468.
13. Yuen KK, Shelley M, Sze WM, et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev. 2006;CD006250.
14. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. 2003;349:1676-1679.
15. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64:281-289.
16. Oh WK, Proctor K, Nakabayashi M, et al. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer. 2007; 109:1090-1096.
17. Lipton A, Goessl C. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone. 2011;48:96-99.
18. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176.
19. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342.
20. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphospho-nates. J Clin Oncol. 2009;27:1564-1571.
21. Fizazi K, Bosserman L, Gao G, et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol. 2009;182:509-516.
22. Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res. 2008;14:6690-6699.
23. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, doubleblind study. Lancet. 2011;377:813-822.
24. Henry D, Von Moos R, Vadhan-Raj S, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur J Cancer. 2011;29:1125-1132.
25. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132-5139.
26. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1987;7:177-188.
28. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50: 1088-1101.
29. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315: 629-634.
30. Patrick D, Cleeland C, Fallowfield L, et al. Effects of denosumab and zoledronic acid on pain interference with daily functioning in patients with castrate-resistant prostate cancer. J Urol. 2011; 185(suppl 4):abstr 711.
31. Patrick D, Fallowfield L, Cleeland C, et al. Effects of denosumab versus zoledronic acid on pain in patients with metastatic breast cancer: results from a randomized, double-blind, double-dummy phase 3 trial. Support Care Cancer. 2010;18(suppl 3):abstr 15-154.
32. Von Moos R, Patrick D, Fallowfield L, et al. Pain management in patients (pts) with advanced cancer (excluding breast and prostate) or multiple myeloma (MM): results from a randomised phase 3 clinical trial of denosumab versus zoledronic acid (ZA). Onkologie. 2010;33(suppl 6):abstr 257.
33. Cleeland CS, Patrick DL, Fallowfield L, et al. Effects of denosumab vs zoledronic acid (ZA) on pain in patients (PTS) with advanced cancer and bone metastases: an integrated analysis of 3 pivotal trials. Paper presented at: 2010 European Society for Medical Oncology; 2010; abstr 3353.
34. Fallowfield L, Patrick D, Body J, et al. Effects of denosumab versus zoledronic acid (ZA) on health-related quality of life (HRQL) in metastatic breast cancer: results from a randomized phase III trial. J Clin Oncol. 2010;28(suppl 15):abstr 1025.
35. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12:6213-6216.
36. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-593.
37. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664.
38. Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733-759.
39. Rogers MJ, Crockett JC, Coxon FP, et al. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2010;49:34-41.
40. Boyce BF, Xing L. Biology of RANK, RANKL, and osteopro-tegerin. Arthritis Res Ther. 2007;9(suppl 1):S1.
41. Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 2008; 1143:123-150.
42. Als-Nielsen B, Chen W, Gluud C, et al. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290:921-928.
43. Yaphe J, Edman R, Knishkowy B, et al. The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam Pract. 2001;18:565-568.
44. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1167-1170.